Autoimmune hemolytic anemia natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 11: Line 11:


==Complications==
==Complications==
* Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).<ref>{{cite journal |author=Zecca M, Nobili B, Ramenghi U, ''et al.'' |title=Rituximab for the treatment of refractory autoimmune hemolytic anemia in children |journal=Blood |volume=101 |issue=10 |pages=3857–61 |year=2003 |month=May |pmid=12531800 |doi=10.1182/blood-2002-11-3547 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12531800}}</ref>
Complications of autoimmune hemolytic anemia include
* Severe [[Anemia (patient information)|anemia]]
*Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).<ref>{{cite journal |author=Zecca M, Nobili B, Ramenghi U, ''et al.'' |title=Rituximab for the treatment of refractory autoimmune hemolytic anemia in children |journal=Blood |volume=101 |issue=10 |pages=3857–61 |year=2003 |month=May |pmid=12531800 |doi=10.1182/blood-2002-11-3547 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12531800}}</ref>
**'''Iron overload''': Autoimmune hemolytic anemia is frequently complicated by iron overload due to frequent [[red blood cell]] transfusions.
*'''End-organ damage from impaired oxygen delivery''': The effects of severe anemia affect a variety of organs and tissues that rely heavily upon oxygen for energy metabolism. If hemoglobin decreases significantly, typically to values lower than 7g/dl, patients can experience impaired oxygen delivery and end-organ hypoxia. If hemoglobin decreases significantly, typically to values lower than 7g/dl, patients can experience impaired oxygen delivery and end-organ hypoxia.
**'''Hypoxic brain injury''': This is a rare but important complication of severe anemia. Low oxygen delivery to the brain as a result of autoimmune hemolytic anemia can result in ischemic injury to neurons and supporting tissue. This is functionally similar to [[cerebrovascular accident]], or [[stroke]], which is due to atherosclerotic or embolic blockage of the cerebral circulation. Patients can experience severe symptoms such as numbness, weakness, paralysis, and [[dysarthria]], or slurred speech. Patients can have significant neurological impairment (including deficits in motor, sensory, cortical, and cerebellar function). Overall, the likelihood of hypoxic brain injury due to autoimmune hemolytic anemia is very low.
**'''Myocardial injury''': Autoimmune hemolytic anemia can result in impaired oxygen delivery to the cardiac tissue. [[Myocardial infarction]] can result from poor oxygen content in the coronary circulation, which is functionally similar to having ischemia due to blockage by an atherosclerotic plaque. Patients can experience severe symptoms such as shortness of breath, fatigue, and decreased exercise tolerance. Anemia is associated with poor outcomes.<ref name="pmid26517509">{{cite journal| author=Park S, Jung CW, Kim K, Kim SJ, Kim WS, Jang JH| title=Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. | journal=Oncotarget | year= 2015 | volume= 6 | issue= 40 | pages= 42803-12 | pmid=26517509 | doi=10.18632/oncotarget.5658 | pmc=4767472 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26517509  }} </ref> Patients can have long-term complications such as congestive heart failure.
**'''[[High-output cardiac failure]]''': Hemolytic anemia can also be associated with high-output cardiac failure, in which the [[ejection fraction]] and [[cardiac output]] are higher than normal. This is a manifestation of impaired oxygen delivery at the tissue level, for which the body compensated by increasing the circulatory output in an attempt to deliver more oxygen to tissues.


==Prognosis==
==Prognosis==

Revision as of 18:33, 3 April 2018

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia natural history, complications and prognosis

CDC on Autoimmune hemolytic anemia natural history, complications and prognosis

Autoimmune hemolytic anemia natural history, complications and prognosis in the news

Blogs on Autoimmune hemolytic anemia natural history, complications and prognosis

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Natural History

Complications

Complications of autoimmune hemolytic anemia include

  • Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).[1]
    • Iron overload: Autoimmune hemolytic anemia is frequently complicated by iron overload due to frequent red blood cell transfusions.
  • End-organ damage from impaired oxygen delivery: The effects of severe anemia affect a variety of organs and tissues that rely heavily upon oxygen for energy metabolism. If hemoglobin decreases significantly, typically to values lower than 7g/dl, patients can experience impaired oxygen delivery and end-organ hypoxia. If hemoglobin decreases significantly, typically to values lower than 7g/dl, patients can experience impaired oxygen delivery and end-organ hypoxia.
    • Hypoxic brain injury: This is a rare but important complication of severe anemia. Low oxygen delivery to the brain as a result of autoimmune hemolytic anemia can result in ischemic injury to neurons and supporting tissue. This is functionally similar to cerebrovascular accident, or stroke, which is due to atherosclerotic or embolic blockage of the cerebral circulation. Patients can experience severe symptoms such as numbness, weakness, paralysis, and dysarthria, or slurred speech. Patients can have significant neurological impairment (including deficits in motor, sensory, cortical, and cerebellar function). Overall, the likelihood of hypoxic brain injury due to autoimmune hemolytic anemia is very low.
    • Myocardial injury: Autoimmune hemolytic anemia can result in impaired oxygen delivery to the cardiac tissue. Myocardial infarction can result from poor oxygen content in the coronary circulation, which is functionally similar to having ischemia due to blockage by an atherosclerotic plaque. Patients can experience severe symptoms such as shortness of breath, fatigue, and decreased exercise tolerance. Anemia is associated with poor outcomes.[2] Patients can have long-term complications such as congestive heart failure.
    • High-output cardiac failure: Hemolytic anemia can also be associated with high-output cardiac failure, in which the ejection fraction and cardiac output are higher than normal. This is a manifestation of impaired oxygen delivery at the tissue level, for which the body compensated by increasing the circulatory output in an attempt to deliver more oxygen to tissues.

Prognosis

References

  1. Zecca M, Nobili B, Ramenghi U; et al. (2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857–61. doi:10.1182/blood-2002-11-3547. PMID 12531800. Unknown parameter |month= ignored (help)
  2. Park S, Jung CW, Kim K, Kim SJ, Kim WS, Jang JH (2015). "Iron deficient erythropoiesis might play key role in development of anemia in cancer patients". Oncotarget. 6 (40): 42803–12. doi:10.18632/oncotarget.5658. PMC 4767472. PMID 26517509.

Template:Hematology


Template:WikiDoc Sources